Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
Related Questions
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Would you discontinue or dose-reduce Tamoxifen in a patient that developed hepatic steatosis?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
